In this episode, Veeva's VP of Commercial Strategy, Doug Caldwell, shares his expertise in working with emerging and mid-sized life sciences companies as they mature their commercial operations. Doug tells us how the pandemic and the resulting period of digital disruption has moved the industry forward by leaps and bounds—and highlights the ways emerging biopharmas are outperforming their larger peers. Don’t miss “Doug Caldwell in Context,” in which he discusses the book that bridges his personal and professional interests and reveals who would attend his meticulously planned ultimate dinner party (and golf match) for four.